Histone deacetylase (HDAC) inhibitors

View All

multiple myeloma
The changing landscape of Multiple Myeloma therapies market

Multiple Myeloma, the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due to the presence of malignant plasma cells in bone marrow. Due to the vigorous proliferation of highly abnormal, unstable cells circulating via the bloodstream and lymph nodes, ...

Find More

HDAC
HDAC (Histone Deacetylase) Inhibitors – A Promising Anti-Cancer Target

Histone deacetylase ( HDAC ) inhibitors are a new class of anti-cancer agents which play important roles in epigenetic or non-epigenetic regulation, including programmed cell death, and cell cycle arrest in cancer cells. Histone deacetylase inhibitors are either naturally occurring or they can be synthetically produ...

Find More